Testing HB0056 in People With Idiopathic Pulmonary Fibrosis
Tests HB0056 compared with placebo in adults with idiopathic pulmonary fibrosis.
Plain-language title generated from the registry record
Registry title: A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
Key facts
- Where
- Changsha and Shanghai, ChinaSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT07909655, who can take part
Where in China
- Xiangya Third Hospital of Central South UniversityChangsha, ChinaNo longer taking part
- Fudan University Affiliated Zhongshan HospitalShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Trial code
- NCT07909655
- Record updated
- 2 November 2026
- Original description
This trial is a 58 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of HB0056, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Treatment of Idiopathic Pulmonary Fibrosis Patients With HB0056
This trial is a 58 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of HB0056, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.
Inclusion: Age 40 to 80, inclusive, at the time of screening; IPF diagnosed within 5 years prior to screening，and whose HRCT during the screening period meets the diagnostic guidelines for idiopathic pulmonary fibrosis jointly released by the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Latin American Thoracic Association (ALAT) in 2022; HRCT diagnosis UIP type/possible UIP type (standard HRCT confirmed by central review in recent 3 months) with or without pathological UIP type/possible UIP type (pathology refers to frozen lung biopsy or surgical/thoracoscopic lung biopsy)；; FVCpp ≥ 45% during screening period and the first day; The percent of predicted DLCO value (corrected by Hb value) at screening is ≥ 30%; pre-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ≥ 0.7; Before randomization, pirfenidone or nidanib with stable dose ≥ 8 weeks can continue to maintain treatment with stable dose during the study period; Or at least 8 weeks before randomization, pirfenidone or nidanib was not used；.
Exclusion: Acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) within 3 months prior to screening and/or during the screening period (investigator-determined); Received experimental treatment for IPF within the first 4 weeks of randomization; Individuals who have received treatment with Namistat or other PDE4 inhibitors within the first 8 weeks of randomization or plan to receive treatment with Namistat or other Phosphodiesterase-4(PDE4) inhibitors during the study period; Have participated in any clinical trials of investigational drugs within 28 days prior to screening or within 5 half lives of the drug (whichever is longer); Acute respiratory or systemic bacterial, viral, or fungal infections requiring treatment within 4 weeks prior to Visit 1 and/or during the screening period; Those who have used prednisone>15mg/day or equivalent dose within the first 2 weeks of randomization and require maintenance.